This inventor holds 1 USPTO granted patent. Top assignee: Neuroceuticals, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Kenji Sunagawa: Innovator in Myocardial Infarction Treatment
Introduction
Kenji Sunagawa, based in Tokyo, Japan, is an accomplished inventor recognized for his significant contributions to medical technology. With a keen focus on innovations aimed at improving cardiac health, he has developed a groundbreaking patent that holds promise for myocardial infarction treatment.
Latest Patents
Sunagawa's notable patent, entitled "Control apparatus for treating myocardial infarction and control method for treating myocardial infarction," presents an advanced stimulation control unit. This apparatus outputs a stimulation signal designed to reduce the myocardial workload by stimulating the vagus nerve through a precisely placed electrode. The invention incorporates a detecting unit to monitor biological information and a setting unit to establish normative thresholds for evaluation. This feedback mechanism allows for adjustments in stimulation signal intensity to maintain biological parameters within safe limits.
Career Highlights
Currently, Kenji Sunagawa is associated with Neuroceuticals, Inc., a company specializing in developing novel treatments for neurological and cardiovascular conditions. His work has had a lasting impact on the healthcare industry, demonstrating the intersection of technology and medicine in improving patient outcomes.
Collaborations
Throughout his career, Sunagawa has collaborated with esteemed colleagues in his field, including Shinya Miike and Keita Saku. Their collective efforts have further advanced research and innovation in cardiac treatment technologies, highlighting the importance of teamwork and collaboration in medical advancements.
Conclusion
In summary, Kenji Sunagawa stands out as a pivotal figure in the realm of medical device innovation. His patent for treating myocardial infarction not only showcases his inventive spirit but also contributes significantly to the evolution of cardiac care. With ongoing advancements and collaborations at Neuroceuticals, Inc., Sunagawa continues to shape the future of medical technology and patient health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile